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BACKGROUND: Cucurbitacin (Cuc) and triterpene-derived natural products exhibit anti-cancer potential in addition to their
conspicuous anti-bacterial and anti-inflammatory activity. Recently, inhibition of Janus kinase 2 (JAK2)/signal transducer and activator
of transcription 3 (STAT3) signaling was shown to underlie the effects of Cuc family on inducing cell death in cancer.
METHOD: We purified Cuc IIa, the active component from the medicinal plant Hemsleya amalils Diels, which shows different structural
modifications from other Cuc derivatives. We investigated the mechanisms of its inhibitory effects on cancer cells in vitro and tumour
growth in vivo.
RESULTS: Cuc IIa induced the irreversible clustering of filamentous actin and arrested cell cycle by the increases in G2/M populations.
Cuc IIa resulted in the reduced phospho-Histone H3 and markedly increased cleavage of poly-(ADP-ribose) polymerase or
PARP, immediate upstream of DNA breakdown as the result of caspase activation, consistent with mitotic blockage-induced cell
death. However, unlike other Cuc members, Cuc IIa did not suppress JAK2/STAT3 phosphorylation or alter phosphorylation of
mitogen-activated protein kinases. Instead, the expression of the cell cycle-regulated Inhibitor of Apoptosis Protein (IAP) survivin was
reduced. Introducing oncoprotein d-catenin, which increased survivin expression and suppressed small GTPase RhoA, reduced
efficacy of Cuc IIa to induce cell death. Supporting the effects of Cuc IIa on actin cytoskeletal signaling, RhoA phosphorylation was
reduced suggesting its increased activity.
CONCLUSION: Cuc IIa is a novel class of anti-cancer drug in suppression of cancer cell expansion by disrupting the actin cytoskeleton
and directing the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3.
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Cancer development is the result of loss of balance in cellular
functions including cell growth, adhesion, division, and apoptosis
(Cotter, 2009). A number of signal transduction pathways are
involved in the alteration of cell functions in cancer (Manning and
Cantley, 2007; Karnoub and Weinberg, 2008). To develop
rationally designed therapies for cancer treatment, intensive
researches aimed at the identification of novel drugs to inhibit
cancer cell-specific signaling or restore cell signaling to the normal
states.
Triterpene-derived natural products from medicinal plants
exhibit conspicuous anti-bacterial and anti-inflammatory effects.
In the past several years, cucurbitacins have become a subject of
intense investigation because this triterpene family induces cancer
cell death (Wu et al, 2002; Sun et al, 2005; Liby et al, 2007) and
many of them inhibit the phosphorylation of Janus kinase 2 (JAK2)
and signal transducer and activator of transcription 3 (STAT3)
(Bromberg et al, 1999; Blaskovich et al, 2003; Sun et al, 2005;
Thoennissen et al, 2009). STAT3, originally identified as an
important regulator of lymphocyte interferon-mediated gene
transcription, is constitutively activated in many cancers (Bromberg
et al, 1999). Although JAK2/STAT3 signaling can conceivably be
controlled at the levels of growth factor ligands, surface receptors
and intracellular downstream target elements, it is previously
reported that cucurbitacins shut down JAK2/STAT3 signaling by
inhibiting their phosphorylation.
Cucurbitacin IIa (Cuc IIa) is a triterpene family component of
natural products with different structural modifications from other
Cuc derivatives. This chemical can be isolated from the Hemsleya
amalils Diels plant. The plant has been used as a homoeopathic
treatment for various diseases in China for centuries and has been
indicated to display anti-cancer potential (Wu et al, 2002).
However, the molecular and cellular mechanisms of its anti-cancer
activities have not been established.
In this study, we demonstrate that Cuc IIa inhibits cancer cell
expansion by disrupting the actin cytoskeleton and mitosis.
However, unlike other Cuc derivatives which induce cell death
through the inhibition of JAK2/STAT3 signaling, Cuc IIa directs
the cells to undergo apoptosis independent of JAK2/STAT3
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sphosphorylation but targets their potential downstream compo-
nent Inhibitor of Apoptosis Protein (IAP)/survivin and poly-(ADP-
ribose) polymerase (PARP) pathways. Therefore, actin cytoskeletal
signaling is the common target of Cuc family’s anti-cancer activity,
which can converge on cell survival machinery through JAK2/
STAT3-dependent and -independent mechanisms.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies against total PARP, cleaved PARP, Histone H3, STAT3,
phospho-STAT3 (tyrosine 705), JAK2, phospho-JAK2 (tyrosine
1007/1008), ERK1/2, and phospho-ERK1/2, were from Cell
Signaling (Danvers, MA, USA). Rabbit anti-phosphorylated RhoA
(serine 188), sepharose beads conjugated anti-RhoA, and sephar-
ose beads conjugated anti-Cdc42 were from Santa Cruz Biotech
(Santa Cruz, CA, USA). Anti-survivin, phospho-Histone H3, and
phosphorylated Rac1/Cdc42 (serine 71) were obtained from
Millipore (Billerica, MA, USA). Monoclonal anti-tubulin (DM1a)
was from Sigma (St Louis, MO, USA). Monoclonal anti-actin
(JL20) and anti-GAPDH were from EMD Science (Gibbstown, NJ,
USA). All other chemicals were from Sigma unless indicated
otherwise.
Extraction and isolation of Cuc IIa from Hemsleya
Dried and finely powdered roots of Xuedan (H. amalils Diell) were
extracted with acetone at room temperature for 10 days and
filtrated. The extracts were concentrated in water bath and
subjected to chromatography on a silica gel column. The crude
Cuc IIa was eluted with chloroform containing increasing volume
of methanol (10–20%). After further purification by ethanol
recrystallisation, Cuc IIa was obtained with over 98% purity, as
determined by HPLC. The structure of Cuc IIa was confirmed by
UV, IR, NMR, and MS analysis (Zhang et al, 2006).
Cell culture
The mouse hepatocellular carcinoma H22, human lung cancer
NCI-H1299, human prostate cancer PC-3, and CWR22Rv-1 were
grown in RPMI 1640 with 10% fetal bovine serum (FBS). The
mouse NIH3T3 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% FBS (Gibco, Carlsbad, CA, USA).
Lewis lung carcinoma (LLC) cell lines were maintained in DMEM.
All cells were incubated at 371Ci n5 %C O 2 environment.
CWR22Rv-1 cells stably transfected with oncoprotein d-catenin
or GFP vector alone (Zeng et al, 2009) were also grown in
RPMI1640 medium with 0.25% Gentamycin (G418) (Gibco).
MTT assay
All cells were treated with Cuc IIa at 1, 10, and 100mgml
 1 for 48h.
The cells were then incubated in MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) (ACROS, Morris Plains,
NJ, USA). DMSO was applied to lyse the cells and release the
formazan purple crystal product. The amount of crystals was read
at an absorbance of 562nm by a microplate reader (Synergy HT,
Bio-Tek, Winooski, VT, USA).
Tumour growth
Mouse hepatocellular carcinoma cell line H22 and Lewis lung
carcinoma cells were inoculated subcutaneously into C57 mice
with or without Cuc IIa treatments. Cuc IIa was formulated in
2-HP-b-CD (2-hydroxypropyl-cycloclextrin) to facilitate solubi-
lisation. 2-HP-b-CD is indicated to be more toxicologically
benign (Gould and Scott, 2005). It has been shown to be well
tolerated in humans so it was adopted for our in vivo studies.
Cuc IIa in different doses was administered either by oral
feeding, peritoneal or intravenous injection. Tumour growth was
monitored and their weight was determined at the end of
experiments. The mice were maintained according to the
Institutional Animal Use Protocol.
Time-lapse imaging
NIH 3T3 cells were transfected with EGFP-actin (Ballestrem et al,
2000) using the transfection reagent Fugene (Roche, Indianapolis,
IN, USA). The coverslip with transfected cells was placed onto the
stage of Zeiss Axiovert inverted fluorescent microscope (Zeiss,
Thornwood, NY, USA) and treated with 10mgml
 1 Cuc IIa. Images
of actin clustering in the cells were recorded using time-lapse
mode through Hamamatsu-Orca-1 digital camera under the
microscope. The camera was set up to record a picture of the
cell every 5min for 4h using MetaMorph (4.6) software (Molecular
Devices, Sunnyvale, CA, USA).
Immunofluorescent light microscopy
PC-3, CWR22Rv-1, and NCI-H1299 cells were fixed in warm 4%
paraformaldehyde. Following permeabilisation in 0.2% Triton
X-100, the cells were stained using mouse monoclonal anti-
a-tubulin DM1a, rabbit polyclonal anti-STAT3, or rabbit anti-
phosphorylated RhoA (Sauzeau et al, 2000a,b). The cells were then
incubated with the appropriate Cy3-conjugated secondary anti-
bodies. The nuclei of the cells were stained with Hoechst 33258.
The filamentous actin of the cells was stained using rhodamine
phalloidin (Molecular Probes, Invitrogen, Carlsbad, CA, USA). The
coverslips were mounted on slides using Anti-Fade medium
(Invitrogen, Carlsbad, CA, USA) and photographed under the
Zeiss Axiovert inverted fluorescent microscope.
Flow cytometry
To determine cell cycle progression, cultured cells were grown to
60% confluency and treated with Cuc IIa at 10mgml
 1 for 16h.
The cells were stained with propidium iodine (PI) before they were
taken for flow cytometry analysis. The DNA content of PI-stained
cells was analysed on a FACScan (BD Biosciences, Palo Alto, CA,
USA) at 488nm excitation and emission detected using a 585nm
band pass filter. The percentage of cells in each phase of cell cycle
(SubG1, G1, S, and G2/M) was determined using a ModFit 3.1
computer program (Varity Software House, Topsham, ME, USA).
The results were analysed by taking the mean and standard error
results for each phase.
Western blot with ECL detection
Cells were treated with Cuc IIa at 1 and 50mgml
 1 for 16h and
lysed in RIPA buffer (1% Triton X-100, 0.5% deoxycholic acid,
0.2% SDS, 150mM sodium chloride, 2mM EDTA) with protease
inhibitor cocktail (Roche) and pepstatin A. After removing cell
debris by centrifugation, protein concentration was determined
using BCA method. Some cell lysates were immunoprecipitated
using anti-RhoA conjugated sepharose beads and then western
blotted with anti-phosphorylated RhoA (serine 188).
The proteins separated by SDS–PAGE were transferred to the
nitrocellulose membrane (Optitran, Whatman GmbH, Dassel,
Germany) for western blot analyses. The primary antibodies used
were against the following antigens: cleaved PARP, PARP, survivin,
Histone H3, STAT3, JAK2, phosphorylated STAT3, phosphorylated
JAK2, phospho-Histone H3, and phosphorylated RhoA, actin, and
GAPDH. After incubation in appropriate secondary antibodies, the
membranes were developed with ECL detection reagents. Protein
amount were semi-quantified in triplicates using Quantity One
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s(Bio-Rad, Hercules, CA, USA). Statistical analyses were performed
and the P-values were assigned with the confidence levels set at 95%.
Detection of DNA ladder with Cuc IIa treatment
PC-3 and CWR22Rv-1 cells were grown to 80% confluence
and treated with Cuc IIa at 5 and 40mgml
 1 for 72h.
The internucleosomal DNA was extracted using Apoptotic DNA
Ladder Extraction Kit (Biovision, Mountain View, CA, USA).
The extracted DNA was run on a 1.2% agarose gel and visualised
using ChemiDoc XRS (Bio-Rad).
RESULTS
Cuc IIa suppresses cancer cell growth and reduces
tumour size
We isolated Cuc IIa (Figure 1A) from the roots of H. amalils
Diels and determined its purity to around 98% (Zhang et al, 2006).
MTT assays were employed during the initial analyses to
determine the effects of Cuc IIa on cancer cell viability. In prostate
cancer CWR22Rv-1 cells, 100mgml
 1 Cuc IIa resulted in
43% cell death (Figure 1B). The prostate cancer PC-3 cells showed
similar response to Cuc IIa as CWR22Rv-1, with 52% of the
cells killed (Figure 1C). Human lung cancer NCI-H1299 cells
showed the greatest response to Cuc IIa with 63.9% of cells died
(Figure 1D). We thus concluded that Cuc IIa reduced cancer cell
viability.
We then applied 1 and 10mgml
 1 Cuc IIa to CWR22Rv-1 cells to
examine cell growth in culture (Figure 1E). Compared with
control cells, CWR22Rv-1 cells treated with 1mgml
 1 Cuc IIa
showed significantly decreased cell numbers by day 2, 4, and 8
following initial cell plating. CWR22Rv-1 cells treated with
10mgml
 1 Cuc IIa showed the reduced growth by day 2 and
completely blocked cell expansion by day 4 and beyond
(Figure 1E).
To determine if Cuc IIa is effective in reducing tumour growth
in vivo, we performed either oral feeding, peritoneal or
intravenous injection of murine transplanted hepatoma H22 cells
in mice. We found that peritoneal injection of Cuc IIa reduced
tumour size in a dose-dependent manner (Table 1) while oral
administration displayed more moderate results (Table 2).
Intravenous injection resulted in a decreased dosing required to
suppress the tumour growth indicating higher inhibition efficiency
(Table 3). We also tested the effectiveness of Cuc IIa against the
growth of LLC model, and the results were quite similar in that it
reduced the tumour size in a dose-dependent manner (see
Supplementary Table SI). Therefore, Cuc IIa suppressed cancer
cell growth and tumour development.
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Figure 1 Cuc IIa suppresses cancer cell expansion. (A) Chemical structure of Cuc IIa. (B) Dose-dependent suppression of prostate cancer CWR22Rv-1
cell expansion measured by MTT assay. (C) Dose-dependent suppression of prostate cancer PC-3 cell expansion measured by MTT assay. (D) Dose-
dependent suppression of lung cancer NCI-H1299 cell expansion measured by MTT assay. The lower absorbance indicates greater cell death. (E) Cell
growth in CWR22Rv-1 with or without Cuc IIa treatments. CWR22Rv-1 cells were treated with 1 or 10mgml
 1 Cuc IIa and the cell numbers were counted
at day 2, 4, and 8. *Po0.05.
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non-reversible aggregation of F-actin
To investigate the molecular and cellular mechanisms of Cuc IIa
effects on suppression of cancer cell expansion, we evaluated cell
morphology using immunofluorescent light microscopy. Rhoda-
mine phalloidin staining of CWR22Rv-1 prostate cancer cell lines
showed that, unlike control cells in which F-actin was distributed
in all of the cytoplasmic compartments (Figure 2Aa and Ac), cells
treated with 50mgml
 1 Cuc IIa for 48h showed severe clustering of
F-actin (Figure 2Ad and Af). The microtubules, as demonstrated
by the anti-tubulin staining, did not show significant changes
(Figure 2B, compare Ba and Bc with Bd and Bf). Therefore, Cuc IIa,
like other Cuc family members, targets actin, but not microtubule
cytoskeleton.
We further examined the dynamics of F-actin structure
treated with Cuc IIa in NIH 3T3 cells that were transfected with
EGFP-actin. Transfected cells were recorded using time-lapse
imaging under the inverted fluorescent microscope for a period of
4h while the program MetaMorph took pictures every 5min
(Figure 2C). The cells treated with 50mgml
 1 Cuc IIa showed
increasing F-actin aggregation with time (Figure 2C, arrows). After
the cells had been treated with Cuc IIa for 2h, the cells were
washed with regular DMEM to rinse off Cuc IIa. After the cells
were washed, they were incubated for an additional 2h to
determine if the alteration of F-actin can be reversed. Time-lapse
recording showed that the F-actin was continuously constricted
and clustered at the different sites in the cells (Figure 2C, arrows
and arrowheads). Therefore, Cuc IIa-induced aggregation of actin
cytoskeleton is irreversible.
Cuc IIa-induced cell apoptosis involves survivin and PARP
pathways
We then performed western blots to determine which molecular
pathways were involved in the cell death induced by Cuc IIa.
CWR22Rv-1, PC-3, and NCI-H1299 cells treated with Cuc IIa at 1
and 50mgml
 1 were analysed using antibodies against proteins in
the cell cycle and apoptosis-related signaling pathways.
Cuc IIa treatments reduced the expression of phospho-Histone
H3, consistent with the disruption of cell cycle progression
(Figures 3A and B). Inhibition of cell cycle can lead to cell death,
and indeed, several apoptosis pathways were activated in Cuc IIa-
treated cancer cells. For example, IAP/survivin is a cell cycle related
survival factor and an inhibitor of cell death as it blocks caspase-3
and -7 from moving the apoptosis signal further downstream
(Li et al, 1998; Olie et al, 2000). In cells treated with Cuc IIa, the
expression of survivin was markedly reduced (Figures 3A and B).
Poly-(ADP-ribose)polymerase is a protein that is critical for cell
survival and is also responsible for repairing DNA breaks (Satoh and
Lindahl, 1992; Cohen, 1997). When it is cleaved by active cleaved
caspase-3, PARP loses its DNA repair function and signals the cell to
move into apoptosis (Cohen, 1997). Our western blots showed that,
while the expression of total PARP remained unchanged, the level of
cleaved PARP was dramatically reduced when the cells were treated
with Cuc IIa (Figures 3A and B). Reduction of cleaved PARP suggests
that the cell’s chromatin and DNA repair machinery was damaged
due to Cuc IIa treatments. One effect of caspase/PARP-mediated
apoptosis is that the DNA of the cell becomes fragmented and is
degraded as the cell dies (Suarez-Huerta et al,2 0 0 0 ) .I n d e e d ,D N A
fragmentation was observed in Cuc IIa-treated PC-3 cells (Figure 3C).
Table 1 The effects of Cuc IIa on mouse H22 liver cancer through abdominal administration
a
Dosage Administration method Animal number Animal body weight (g) Cancer weight (g) Inhibition
Sample (mgkg
 1 per day) Ig 10qd Start/end Start/end X±s.d. efficiency
Cuc IIa 90 Ig 10qd 10/9 21.1/27.6 1.31±0.12 57.05
Cuc IIa 60 Ig 10qd 10/10 21.0/24.6 1.49±0.12 51.05
Cuc IIa 30 Ig 10qd 10/10 20.8/25.4 1.95±0.12 36.07
Control Solvent Ig 10qd 20/20 20.8/25.9 3.05±0.28
aCompared with control, Po0.01. The difference is significant.
Table 2 The effects of Cuc IIa on mouse H22 liver cancer through pouring into stomach
a
Dosage Administration method Animal number Animal body weight (g) Cancer weight (g) Inhibition
Sample (mgkg
 1 per day) Ig 10qd Start/end Start/end X±s.d. efficiency
Cuc IIa 90 Ig 10qd 10/10 19.1/25.7 1.96±0.16 38.17
Cuc IIa 60 Ig 10qd 10/10 19.3/26.3 2.14±0.20 32.09
Cuc IIa 30 Ig 10qd 10/10 19.0/26.0 2.31±0.21 27.13
Control Solvent Ig 10qd 10/10 19.3/26.5 3.17±0.32
aCompared with negative control, Po0.01. The difference is significant.
Table 3 The effects of Cuc IIa on mouse H22 liver cancer through vein injection
a
Dosage Administration method Animal number Animal body weight (g) Cancer weight (g) Inhibition
Sample (mgkg
 1 per day) Ig 10qd Start/end Start/end X±s.d. efficiency
Cuc IIa 15 Ig 10qd 10/10 19.5/25.3 1.48±0.11 55.02
Cuc IIa 10 Ig 10qd 10/10 19.3/25.9 1.76±0.08 44.12
Cuc IIa 5 Ig 10qd 10/10 19.4/25.1 2.13±0.20 32.38
Control Solvent Ig 10qd 10/10 19.4/26.0 3.15±0.44
aCompared with negative control, Po0.01. The difference is significant.
Cucurbitacin IIa and cancer
C Boykin et al
784
British Journal of Cancer (2011) 104(5), 781–789 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sTo support the notion that the reduction of survivin expression
accounted at least partially for the Cuc IIa effects, we applied Cuc IIa
to CWR22Rv-1 cells stably overexpressing d-catenin, an onco-
protein which upregulates survivin expression (Zeng et al, 2009)
and inhibits actin regulatory protein small GTPase RhoA (Kim et al,
2008). We used flow cytometry to document cell cycle progression
profiles and cell death. Cells were treated with 10mgml
 1 Cuc IIa for
16h and stained with PI. Compared with cells without d-catenin
overexpression in the absence of Cuc IIa treatment, cells without
d-catenin overexpression when treated with Cuc IIa resulted in a
46% reduction of G1 phase, but a decreased S phase to only 20%
while having a 5.5-fold increase in G2/M populations, indicating a
block after S phase (Figure 3D, Con-d and Cuc IIa-d). The cells
treated with Cuc IIa also showed a 2.7-fold increase in sub-G1
phases (Figure 3D, Con-d and Cuc IIa-d). The actin cytoskeleton is
critically involved in mitosis and cytokinesis. Failed cytokinesis
would show increased G2/M cell numbers. This data is therefore
consistent with the disruption of actin cytoskeleton as seen in
Figure 2. The 2.7-fold increase in sub-G1 population indicated the
increased cell death, probably due to delayed cell cycle progression.
Compared with cells with d-catenin overexpression in the absence
of Cuc IIa treatment, Cuc IIa treatment in d-catenin overexpressing
cells led to a moderate decrease in S phase and a slight increase in
G2/M population (Figure 3D, Conþd and Cuc IIaþd). However,
there were no significant changes in G1 and sub-G1 population
when compared with cells without Cuc IIa treatment (Figure 3D,
Conþd and Cuc IIaþd), consistent with the hypothesis that
reduced survivin expression is at least a partial mechanism for Cuc
IIa-mediated cell death (Figures 3A and B).
Cuc IIa does not inhibit JAK2 and STAT3 phosphorylation
Recently, some Cuc derivatives have been reported to induce cell
apoptosis through JAK2/STAT3 signaling pathway (Kisseleva et al,
2002; Sun et al, 2005; Thoennissen et al, 2009). As survivin is a
potential downstream target of JAK2/STAT3 pathway (Scheper
*
0:00
1:00
2:00
3:00
4:00
*
*
*
Figure 2 Cuc IIa alters actin cytoskeleton but not microtubule organisation. (A) Cuc IIa induces a dramatic actin clustering in cultured CWR22Rv-1 cells.
(a–c) Cells without Cuc IIa treatment. (d–f) Cells treated with 50mgml
 1 Cuc IIa. Arrows indicate rhodamine phalloidin staining of F-actin. Bar: 20mm.
(B) Cuc IIa does not induce changes in microtubule organisation. (a–c) Cells without Cuc IIa treatment. (d–f) Cells treated with 50mgml
 1 Cuc IIa.
(C) Time-lapse imaging of NIH3T3 cells transfected with EGFP-actin shows gradual aggregation of actin cytoskeleton and the alteration is not reversible. The
cells were grown to 60% confluency and were then transfected with EGFP-actin. The cells were treated with 50mgml
 1 Cuc IIa over a 2-h period followed
by a 2-h recovery. Time-lapse images were taken every 5 min. After 2h of Cuc IIa treatment, the drug was removed and cells were rinsed. The cells were
then recorded for an additional 2h to assess the recovery of actin distribution. Arrows indicate points of increasing actin aggregation with time. Bar: 15mm.
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set al, 2007; Glienke et al, 2010), we further explored whether Cuc
IIa also inhibited cancer cell expansion by inhibiting JAK2/STAT3
activation. Western blots showed that CWR22Rv-1 and NCI-H1299
cells expressed STAT3 and JAK2 (Figure 4A). However, treatment
with Cuc IIa up to 50mgml
 1 did not inhibit STAT3 or JAK2
phosphorylation in CWR22Rv-1 cells, and only marginally reduced
JAK2 phosphorylation in NCI-H1299 cells. Therefore, these data
suggested that Cuc IIa exerted the cell-death inducing effects
downstream of JAK2/STAT3 phosphorylation or expression in
these cancer types.
STAT3 activation by JAK2 leads to its nuclear translocation. We
therefore, examined whether Cuc IIa changed the STAT3 distribu-
tion. NCI-H1299 cells with or without treatment of Cuc IIa were
fixed and double labeled with anti-STAT3 and rhodamine
phalloidin to label F-actin. Control cells without Cuc IIa treatment
showed cytoplasmic and peripheral F-actin staining as expected
(Figure 4Ba). STAT3 showed mixed nuclear and cytoplasmic
distribution (Figure 4Bb). F-actin only partially co-localised with
STAT3 (Figure 4Bc). Cells treated with Cuc IIa showed clustering
of F-actin (Figure 4Bd) consistent with above observations in
prostate cancer cells (Figure 2A) and NIH 3T3 cells (Figure 2C).
While cells treated with Cuc IIa showed remarkable morphological
changes, STAT3 still showed a mixed nuclear and cytoplasmic
distribution (Figure 4Be and Bf). Additionally, signaling through
mitogen-activated protein kinase (MAPK) or extracellular signal-
regulated kinase (ERK) is believed to cross talk with JAK2/STAT3
signaling pathway. Western blot showed no consistent activation
or inhibition of ERK phosphorylation (Figure 4C). These studies
collectively suggested that Cuc IIa-mediated suppression of cancer
cell expansion is not dependent on the inhibition of JAK2/STAT3
phosphorylation, expression, or distribution, nor is it dependent
on MAPK phosphorylation.
Cuc IIa induces RhoA phosphorylation
All reported Cuc derivatives display a common targeting feature;
that is, they alter actin cytoskeleton organisation (Haritunians
et al, 2008; Maloney et al, 2008). A distinct signaling pathway
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Figure 3 Cuc IIa induces cell cycle alteration and apoptosis involving survivin and PARP. (A) Western blots showing Cuc IIa-induced Histone H3
phosphorylation, increased cleavage of PARP, and reduced survivin in prostate cancer CWR22Rv-1 and PC-3 cells as well as lung cancer NCI-H1299 cells.
GAPDH is used as loading control. Molecular weight markers are on the left. (B) Semi-quantification of Western blots showing Cuc IIa-induced Histone H3
phosphorylation, increased cleavage of PARP, and reduced survivin expression in prostate cancer CWR22Rv-1 and PC-3 cells as well as lung cancer NCI-
H1299 cells. *Po0.01. (C) Example of DNA fragmentation demonstrated as evidence of apoptosis in PC-3 cells treated with Cuc IIa. In all, 40mgml
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IIa induced DNA fragmentation. (D) Flow cytometry analyses demonstrating that the Cuc IIa-induced increases in cell death are suppressed by d-catenin
transfection. Con-d: Control Cells without d-catenin overexpression; Conþd: Control Cells with d-catenin overexpression; Cuc IIa-d: Cuc IIa-treated cells
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sdirectly impacting the actin cytoskeletal organisation is the Rho
family small GTPases (Lu et al, 2009). Rho GTPase pathway also
interacts with STAT3 signaling (Debidda et al, 2005). Given the
phenotypes of cell shape changes and the retraction of cellular
protrusions (Figures 2A and C) that are characteristic of RhoA
activation, we investigated whether RhoA signaling is altered by
Cuc IIa treatments in cancer cells. Western blots showed that the
serine 188 phosphorylation of RhoA, which inhibits the RhoGDI
interactions with RhoA (Sauzeau et al, 2000a,b), was reduced in
Cuc IIa-treated CWR22Rv-1 cells (Figure 4D, left panel). The
phosphorylation of serine 71 on Rac1/Cdc42, which is an indicator
of Rac1/Cdc42 inactivation (Kwon et al, 2000), was not changed by
Cuc IIa treatment in CWR22Rv-1 cells (Figure 4D, right panel). We
confirmed this result by immunofluorescent light microscopy that
RhoA phosphorylation at serine 188 was suppressed in CWR22Rv-1
cells (Figure 4E, compare a with c).
DISCUSSION
Natural occurring medicinal products have made crucial
contributions to anti-cancer therapies, such as taxane-based
chemo-drugs targeting mitotic microtubule cytoskeletons (Pezzuto,
1997). Originally isolated from the plant Taxus brevifolia Nutt, this
drug acts on cancer cells by stabilising microtubule cytoskeleton so
that the filaments are not able to breakdown (Torres and Horwitz,
1998; Cassinelli et al, 2004). As the cell moves through mitosis, the
cell is arrested at anaphase (Lanzi et al, 2001). The arrested cell
most often goes through apoptosis due to mitotic failure; however,
some cells can complete mitosis and then undergo programmed
cell death (Shi et al, 2008).
Cuc is a novel family of anti-cancer drugs from several plants
and has received increasing attention in recent years for its
apoptosis-inducing effects across multiple cell lines (Wu et al,
2002; Yang et al, 2007; Thoennissen et al, 2009). In our current
study, Cuc IIa suppressed cancer cell expansion in cell culture as
well as in tumour bearing mouse models, providing a new drug
candidate for anti-cancer therapy. Oral feeding had more moderate
effects on reducing tumour size, indicating that the first pass
through liver may limit effective drug access to the tumours. One
of our future researches will focus on improving solubility and
bioavailability of Cuc IIa in the in vivo studies.
While the overwhelming evidences pointed to the alteration of
actin cytoskeletal organisation as the common target, several
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Figure 4 Cuc IIa does not inhibit STAT3/JAK2 phosphorylation but alters RhoA. (A) Western blots of STAT3 and JAK2 in prostate cancer and lung
cancer cells treated with or without Cuc IIa. Note that there is no significant change in total STAT3 and JAK2 expression and phosphorylation in CWR22Rv-1
cells or NCI-H1299 cells. GAPDH immunoreactivity is used as loading control. Molecular weight markers are on the left. (B) Double labeling
immunofluorescent light microscopy showing that STAT3 distribution is not changed with or without Cuc IIa. (a–c) Cells without Cuc IIa treatment. (d–f)Cells
treated with Cuc IIa. Note: actin in Cuc IIa-treated cells are highly aggregated and clustered. (C) Western blots showing that there are no consistent changes in
ERK expression and phosphorylation levels in cells treated with or without Cuc IIa. Actin immunoreactivity is used as loading control. Molecular weight makers
are indicated on the left. (D) Reduced phosphorylation of small GTPase RhoA but not Rac1/Cdc42 in cells treated with Cuc IIa. Left panel: western blots
showing that while total RhoA expression is not changed, the serine 188 phosphorylation of RhoA is reduced in CWR22Rv-1 cells treated with 50mgml
 1 Cuc
IIa. Right panel: western blots showing that both the total Rac1/Cdc42 expression and their serine 71 phosphorylation are not changed in CWR22Rv-1 cells
treated with 50mgml
 1 Cuc IIa. Molecular weight makers are indicated on the left. (E) Immunofluorescent light microscopy showing that while control,
untreated CWR22Rv-1 cells show a basal serine 188 phosphorylation of RhoA (a, d, and g), Cuc IIa treatments significantly reduce RhoA phosphorylation( b ,e ,
and h indicate cells treated with 1mgml
 1 Cuc IIa but c, f, and i indicate cells treated with 50mgml
 1 Cuc IIa). g, h, and i: background fluorescence.
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sreports showed that the induction of apoptosis is mediated
through JAK2/STAT3 signaling pathway. The present study
focused on Cuc IIa purified from the Chinese medicinal plant
H. amalils and demonstrated, for the first time, that Cuc IIa
disrupted actin cytoskeleton and induced apoptosis through novel
pathways involving survivin and PARP but independent of JAK2/
STAT3 phosphorylation, expression, and distribution.
It has been suggested that the inhibition of JAK2/STAT3
underlies the apoptosis when cancer cells are treated with Cuc.
Sun et al (2005) showed that Cuc effectively inhibited cancer cell
expansion only in STAT3-expressing cells. However, recent study
showed that in certain cancer cells without harbouring activated
STAT3, K-Ras protected cells from Cuc-induced apoptosis
(Escandell et al, 2008). It was found that the protective effects
can be removed when p53 and p21 were deleted, further
supporting the inhibition of mitosis as the initiating event of
Cuc-induced apoptosis. Our study is consistent with the observa-
tions of Cuc effects on mitosis. We found that even though
prostate cancer cells CWR22Rv-1 and lung cancer cells NCI-H1299
displayed JAK2/STAT3 expression and activating phosphorylation,
Cuc IIa still induced apoptosis without clearly inhibiting JAK2/
STAT3 phosphorylation. Cuc IIa also did not alter nuclear/
cytoplasmic distribution of STAT3. We showed that the cell cycle
was disrupted with reduced phospho-Histone H3 and survivin.
The CWR22Rv-1 cells with overexpression of survivin and
inhibition of RhoA protected cancer cells from Cuc IIa to some
extent, suggesting that mitotic-related pathways involving survivin
(which could be cooperating with p53 and p21 pathway) are
potential targets to enhance Cuc IIa’s anti-cancer potential.
Therefore, not all Cuc family members induce apoptosis by
directly inhibiting JAK2/STAT3. Rather, they could target the
converging downstream elements such as survivin, indicating a
broader benefit of applying Cuc derivatives to attack cancer cells
from multiple points.
One common effect of Cuc derivatives is the disruption of actin
cytoskeleton (Duncan et al, 1996; Graness et al, 2006; Maloney
et al, 2008; Momma et al, 2008). This effect is universal for
different Cuc derivatives isolated from a variety of sources (e.g.,
Cuc B, Cuc I, and Cuc E). The different roles of actin in cell
division (cytokinesis) from microtubules (chromosomal move-
ment) underscore the importance of identification of Cuc as novel
anti-cancer drugs targeting actin in supporting the established
anti-cancer drug taxol targeting microtubules. We thus hypothe-
sise that Cuc IIa arrests cell cycle progression and results in cell
death in the following working model (Figure 5). Cuc family
disrupts actin dynamics, which initiates two events of cascades in
cancer cells. It can inhibit JAK2/STAT3 signaling pathway directly
in some cells harbouring activated STAT3. It can also lead to the
downregulation of survivin downstream of JAK2/STAT3 without
directly targeting JAK2/STAT3 phosphorylation. The failed cyto-
kinesis activates apoptosis pathways, with reduced phosphoryla-
tion level of Histone H3 and increased chromatin damage. The
reduced PARP function further impairs the repair of damaged
DNA, thus suppresses the cell cycle accelerating the apoptosis in
p53 and p21-mediated pathways. Therefore, while multiple
signaling pathways may be targeted by Cuc derivatives, we
propose that the initiating event is the disruption of actin
cytoskeleton and its associated signaling events. Significantly, the
establishment of a mitotic microtubule modulator such as
paclitaxel and actin disrupter such as Cuc IIa will have far
reaching implications in future oncologic treatments, as they can
potentially suppress two distinct major molecular processes of
cancer cell cycle to combat resistances. The further development
of Cuc and its improved derivatives may provide unique
therapeutic potential to inhibit cancer cell expansion.
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